Abstract:Proper evaluation of therapeutic responses in Chagas disease is hampered by the prolonged persistence of antibodies to Trypanosoma cruzi measured by conventional serological tests and by the lack of sensitivity of parasitological tests. Previous studies indicated that tGPI-mucins, an α-Gal (α- d -Gal p (1→3)-β- d -Gal p (1→4)- d -GlcNAc)-rich fraction obtained from T . cruzi trypomastigotes surface coat, elicit a strong and protective antibody response in infected individuals, which disappears soon after successful treatment. The cost and technical difficulties associated with tGPI-mucins preparation, however, preclude its routine implementation in clinical settings. We herein developed a neoglycoprotein consisting of a BSA scaffold decorated with several units of a synthetic α-Gal antigenic surrogate (α- d -Gal p (1→3)-β- d -Gal p (1→4)-β- d -Glc p ). Serological responses to this reagent, termed NGP-Tri, were monitored by means of an in-house enzyme-linked immunosorbent assay (α-Gal-ELISA) in a cohort of 82 T . cruzi -infected and Benznidazole- or Nifurtimox-treated children (3 days to 16 years-old). This cohort was split into 3 groups based on the age of patients at the time of treatment initiation: Group 1 comprised 24 babies (3 days to 5 months-old; median = 26 days-old), Group 2 comprised 31 children (7 months to 3 years-old; median = 1.0-year-old) and Group 3 comprised 26 patients (3 to 16 years-old; median = 8.4 years-old). A second, control cohort (Group 4) included 39 non-infected infants (3 days to 5 months-old; median = 31 days-old) born to T . cruzi -infected mothers. Despite its suboptimal seroprevalence (58.4%), α-Gal-ELISA yielded shorter median time values of negativization (23 months [IC 95% 7 to 36 months] vs 60 months [IC 95% 15 to 83 months]; p = 0.0016) and higher rate of patient negative seroconversion (89.2% vs 43.2%, p < 0.005) as compared to conventional serological methods. The same effect was verified for every Group, when analyzed separately. Most remarkably, 14 out of 24 (58.3%) patients from Group 3 achieved negative seroconversion for α-Gal-ELISA while none of them were able to negativize for conventional serology. Detailed analysis of patients showing unconventional serological responses suggested that, in addition to providing a novel tool to shorten follow-up periods after chemotherapy, the α-Gal-ELISA may assist in other diagnostic needs in pediatric Chagas disease. The tools evaluated here provide the cornerstone for the development of an efficacious, reliable, and straightforward post-therapeutic marker for pediatric Chagas disease. The limits of the current criterion for cure, i.e., negative seroconversion determined by conventional serology, and the lack of validated and sensitive markers for early assessment of response to trypanocidal drugs in Chagas disease stress the necessity of novel therapeutic response markers. Towards this goal, we herein developed by synthetic chemistry a neoglycoprotein bearing an α-Gal antigenic surrogate, termed NGP-Tri, and evaluated its performance in a large cohort of T . cruzi -infected and treated children. An α-Gal-ELISA built upon NGP-Tri showed a very good performance on the assessment of therapy efficacy, as it displayed significantly shorter median time value of negativization and higher rate of patient negative seroconversion as compared to conventional serology methods. These findings indicate that the tools developed here, as well as optimized versions derived from them, should have a positive impact on the clinical management of Chagas disease and the identification and/or clinical validation of novel drug candidates for the treatment of T . cruzi infections.

Inter-Laboratory Harmonization Study and Prospective Evaluation of the PURE- T. cruzi -LAMP Assay for Detecting Parasite DNA in Newborn's Dried Blood Spots

Evaluation and validation of a PrintrLab-based LAMP assay to identify Trypanosoma cruzi in newborns in Bolivia: a proof-of-concept study

Loop-Mediated Isothermal Amplification of Trypanosoma cruzi DNA for Point-of-Care Follow-Up of Anti-Parasitic Treatment of Chagas Disease

A Nested Real-Time Pcr Assay for the Quantification of Plasmodium Falciparum Dna Extracted from Dried Blood Spots

Development of a Colorimetric Loop-Mediated Isothermal Amplification Assay for the Detection of Trypanosoma cruzi in Low-Resource Settings

Comparative evaluation of lateral flow assays to diagnose chronic Trypanosoma cruzi infection in Bolivia

Comparative evaluation of four rapid diagnostic tests that detect human Trypanosoma cruzi- specific antibodies to support diagnosis of Chagas Disease in urban population of Argentina

TropD-Detector: A CRISPR/LbCas12a-Based system for rapid and sensitive screening of Trypanosoma cruzi in Chagas vectors and reservoirs

Quantitative Laser Biospeckle Method for the Evaluation of the Activity of Trypanosoma cruzi Using VDRL Plates and Digital Analysis

Treponema pallidum PCR with blood and cerebrospinal fluid of newborns exposed and not exposed to syphilis during pregnancy

Comparative Assessment of Two Commercial Real-Time PCR Assays for the Diagnosis of Trypanosoma cruzi DNA in Serum

Parasite Burden of Trypanosoma cruzi in Whole Blood and Buffy Coat Determined by Real-Time PCR in Individuals with Chronic Chagas Disease

Comparison between Enzyme Immunoassays Performed on Samples of Dried Blood and Serum for Toxoplasmosis Prenatal Screening: Population-based Study

How effective are rapid diagnostic tests for Chagas disease?

Colorimetric and Real-Time Loop-Mediated Isothermal Amplification (LAMP) for Detection of Loa loa DNA in Human Blood Samples

An α-Gal antigenic surrogate as a biomarker of treatment evaluation in Trypanosoma cruzi -infected children. A retrospective cohort study

Development and performance evaluation of a qPCR-based assay for the fully automated detection of group B Streptococcus (GBS) on the Panther Fusion Open Access system

A guide for the generation of repositories of clinical samples for research on Chagas disease

Rapid and Sensitive Detection of Babesia Bovis and Babesia Bigemina by Loop-Mediated Isothermal Amplification Combined with A Lateral Flow Dipstick

Serial ‘deep-sampling’ PCR of fragmented DNA reveals the wide range of Trypanosoma cruzi burden among chronically infected hosts and allows accurate monitoring of parasite load following treatment

Parasitic Effects on the Congenital Transmission of Trypanosoma cruzi in Mother–Newborn Pairs